US-based biotechnology firm Cavion has started patient enrolment in a Phase II clinical trial (T-CALM Study) of CX-8998 to treat essential tremor (ET).

CX-8998 is an oral calcium channel modulator being developed to selectively regulate T-type channels called Cav3 that control firing and signalling between neurons.

The T-type calcium channel modulator is intended to restore natural rhythms of the brain.

Designed to enrol 92 patients at 18 medical research centres in the country, the Phase II trial will evaluate the efficacy of CX-8998 to decrease tremors and improve quality of life.

The multi-centre, randomised, double-blind, placebo-controlled, parallel-group trial will assess subjects through standard clinical trial scales and digital markers to objectively quantify tremor.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

"We believe that Cavion’s new therapy may significantly improve the quality of life of people with essential tremor, offering hope to them and their families."

Cavion chief medical officer and research and development executive vice-president Spyros Papapetropoulos said: “We believe that Cavion’s new therapy may significantly improve the quality of life of people with essential tremor, offering hope to them and their families.”

The trial’s primary outcome measure is change in tremor from baseline to day 28 on the essential tremor rating assessment scale (TETRAS) Performance.

Expected to be completed next year, the trial will assess increasing doses of CX-8998 and involve videotaping of patients in order to minimise rater bias during TETRAS assessment.

The firm plans to conduct an additional sub-study with electrophysiological measures to investigate the effect of CX-8998 on neuronal networks.

The sub-study will utilise an electroencephalography (EEG) and magnetoencephalography (MEG) to record power-spectral brain activity in certain neuro-anatomical locations.